Washington, D.C. (January 20, 2026) - The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Stemline Therapeutics, a Menarini Group Company, has joined the organization, strengthening its advocacy on behalf of policies that protect American leadership in medical research and improve the lives of patients.

"Stemline Therapeutics' commitment to advancing innovative cancer therapies makes them a valuable addition to our organization," said Stephen J. Ubl, President and CEO of PhRMA. "They understand the difficult challenges of researching and developing innovative treatments-and the critical role of strong public policies to deliver new therapies to patients. Their expertise, dedication to patients, and continued investment in U.S.-based cutting edge research will strengthen our efforts to promote policies that support biopharmaceutical innovation and improve health outcomes for patients."

Based in New York City, New York, Stemline Therapeutics, a Menarini Group Company is a commercial-stage biopharmaceutical research company focused on the development of novel oncology therapies. With two first in class cancer medicines already available to patients, the company has 19 oncology development programs for new medicines underway. Through its partnership with PhRMA, the company will collaborate with industry leaders to advance public policies that support a robust research ecosystem and help ensure patients have access to life-changing therapies.

"We are in a renaissance in biopharmaceutical innovation, with unprecedented advances transforming the way we discover new therapies for cancer and other devastating diseases," said Elcin Barker Ergun, Chief Executive Officer at Menarini Group. "We've worked diligently to expand our pipeline of new medicines and our presence in the United States where bold science and patient impact meet. Strengthening our engagement with policymakers and industry partners will help ensure that innovation continues to bring life-changing treatments to patients."

Stemline is the fourth biopharmaceutical company to join in the last year. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States. To learn more about how the biopharmaceutical industry is investing in America, visit Innovation.org/American-investment.  

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. PhRMA member companies have invested more than $850 billion in the search for new treatments and cures over the last decade, supporting nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.Innovation.org
www.VotersforCures.org
www.MAT.org
www.LinkedIn.com/Company/PhRMA
www.X.com/PhRMA